{'fraction_non_alphanumeric': 0.025612472160356347, 'fraction_numerical': 0.0022271714922048997, 'mean_word_length': 6.0234375, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In vivo topical application of acetyl aspartic acid increases fibrillin‐1 and collagen IV deposition leading to a significant improvement of skin firmness

Acetyl aspartic acid (A‐A‐A) was discovered through gene array analysis with corresponding Cmap analysis. We found that A‐A‐A increased keratinocyte regeneration, inhibited dermal matrix metalloprotease (MMP) expression and relieved fibroblast stiffness through reduction of the fibroblast stiffness marker F‐actin. Dermal absorption studies showed successful delivery to both the epidermal and dermal regions, and in‐use trial demonstrated that 1% A‐A‐A was well tolerated. In this study, the aim was to investigate whether A‐A‐A could stimulate the synthesis of extracellular matrix supporting proteins in vivo and thereby improving the viscoelastic properties of human skin by conducting a dual histological and biophysical clinical study.